• +1-646-491-9876
    • +91-20-67278686

    Search

    Warts Pipeline Review H2 2017

    Warts Pipeline Review H2 2017

    • Report Code ID: RW0001884154
    • Category Pharmaceuticals
    • No. of Pages 86
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Warts - Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Warts - Pipeline Review, H2 2017, provides an overview of the Warts (Infectious Disease) pipeline landscape.

    Warts are skin growth that is caused by virus called human papillomavirus (HPV) . HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Warts - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 16, 1, 6 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

    Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Publisher Report Coverage 5
    Warts - Overview 6
    Warts - Therapeutics Development 7
    Pipeline Overview 7
    Pipeline by Companies 8
    Pipeline by Universities/Institutes 11
    Products under Development by Companies 12
    Products under Development by Universities/Institutes 14
    Warts - Therapeutics Assessment 15
    Assessment by Target 15
    Assessment by Mechanism of Action 17
    Assessment by Route of Administration 19
    Assessment by Molecule Type 21
    Warts - Companies Involved in Therapeutics Development 23
    Aclaris Therapeutics Inc 23
    Agilvax Inc 23
    Aviragen Therapeutics Inc 24
    BioMAS Ltd 24
    Cutanea Life Sciences Inc 25
    Cytovation AS 25
    Foamix Pharmaceuticals Ltd 26
    G&E Herbal Biotechnology Co Ltd 26
    Laboratories Ojer Pharma SL 27
    LEO Pharma A/S 27
    Nielsen Biosciences Inc 28
    Novan Inc 28
    Novartis AG 29
    Promius Pharma LLC 29
    RXi Pharmaceuticals Corp 30
    Tamir Biotechnology Inc 30
    Zydus Cadila Healthcare Ltd 31
    Warts - Drug Profiles 32
    (digoxin + furosemide) - Drug Profile 32
    854-A - Drug Profile 34
    Albicin - Drug Profile 35
    AS-101 - Drug Profile 36
    AX-03 - Drug Profile 38
    BTA-074 - Drug Profile 40
    CyPep-1 - Drug Profile 42
    DFD-05 - Drug Profile 43
    FIT-039 - Drug Profile 44
    furosemide - Drug Profile 45
    human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile 46
    human papillomavirus vaccine - Drug Profile 47
    human papillomavirus vaccine - Drug Profile 48
    hydrogen peroxide - Drug Profile 49
    imiquimod - Drug Profile 52
    imiquimod SR - Drug Profile 53
    ingenol mebutate - Drug Profile 54
    interferon alfa-2b - Drug Profile 56
    LFX-453 - Drug Profile 57
    omiganan pentahydrochloride - Drug Profile 58
    povidone iodine - Drug Profile 60
    PP-210 - Drug Profile 61
    ranpirnase - Drug Profile 62
    RKP-00156 - Drug Profile 65
    Samcyprone - Drug Profile 66
    SB-206 - Drug Profile 68
    SRT-100 - Drug Profile 70
    VP-100 - Drug Profile 72
    Warts - Dormant Projects 73
    Warts - Discontinued Products 74
    Warts - Product Development Milestones 75
    Featured News & Press Releases 75
    Appendix 83
    Methodology 83
    Coverage 83
    Secondary Research 83
    Primary Research 83
    Expert Panel Validation 83
    Contact Us 83
    Disclaimer 84

    List of Tables

    Number of Products under Development for Warts, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Warts - Pipeline by Aclaris Therapeutics Inc, H2 2017
    Warts - Pipeline by Agilvax Inc, H2 2017
    Warts - Pipeline by Aviragen Therapeutics Inc, H2 2017
    Warts - Pipeline by BioMAS Ltd, H2 2017
    Warts - Pipeline by Cutanea Life Sciences Inc, H2 2017
    Warts - Pipeline by Cytovation AS, H2 2017
    Warts - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017
    Warts - Pipeline by G&E Herbal Biotechnology Co Ltd, H2 2017
    Warts - Pipeline by Laboratories Ojer Pharma SL, H2 2017
    Warts - Pipeline by LEO Pharma A/S, H2 2017
    Warts - Pipeline by Nielsen Biosciences Inc, H2 2017
    Warts - Pipeline by Novan Inc, H2 2017
    Warts - Pipeline by Novartis AG, H2 2017
    Warts - Pipeline by Promius Pharma LLC, H2 2017
    Warts - Pipeline by RXi Pharmaceuticals Corp, H2 2017
    Warts - Pipeline by Tamir Biotechnology Inc, H2 2017
    Warts - Pipeline by Zydus Cadila Healthcare Ltd, H2 2017
    Warts - Dormant Projects, H2 2017
    Warts - Discontinued Products, H2 2017

    List of Figures

    Number of Products under Development for Warts, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Aclaris Therapeutics Inc
    Agilvax Inc
    Aviragen Therapeutics Inc
    BioMAS Ltd
    Cutanea Life Sciences Inc
    Cytovation AS
    Foamix Pharmaceuticals Ltd
    G&E Herbal Biotechnology Co Ltd
    Laboratories Ojer Pharma SL
    LEO Pharma A/S
    Nielsen Biosciences Inc
    Novan Inc
    Novartis AG
    Promius Pharma LLC
    RXi Pharmaceuticals Corp
    Tamir Biotechnology Inc
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//warts-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//warts-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//warts-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments